Why the study?
Persistently high blood pressure remains the leading risk factor for mortality worldwide, prompting the need to identify potential drug targets for hypertension.
Do specific gene alleles reduce hypertension and mortality risks in participants from the UK Biobank and FinnGen study?
Do specific gene alleles reduce hypertension and mortality risks in participants from the UK Biobank and FinnGen study?
Answers are grounded in this paper and cite their sources.
Mendelian randomization identified potential genetic targets associated with lower hypertension-specific mortality, offering new directions for antihypertensive drug development.
BACKGROUND: Persistently high blood pressure remains the leading risk factor for mortality worldwide. This study aims to identify potential drug targets for hypertension. METHODS: Mendelian randomization was used to identify therapeutic targets for hypertension. Genome-wide association study summary statistics were obtained from the UK Biobank and FinnGen study. Cis-expression quantitative trait loci from the eQTLGen Consortium served as genetic instruments. Colocalization analysis evaluated the likelihood of shared causal variants between single-nucleotide polymorphisms influencing hypertension and gene expression. Survival analysis of UK Biobank data assessed hypertension and mortality risks across participants with different gene alleles. RESULTS: gene showed a lower hypertension-specific mortality rate. CONCLUSIONS: Drug target Mendelian randomization studies offer new directions for hypertension treatment, providing insights into its mechanisms and robust targets for developing antihypertensive drugs.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: